uniQure stock heads toward November 4 results update
Published on 11/01/2026 at 12:31 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSuniQure prepares for quarterly results
- uniQure plans to release its third-quarter 2026 financial results before the market opens on November 4.
- The company has scheduled an earnings webcast for November 4 from 8:30 a.m. to 9:30 a.m. Eastern Time.
- Recent investor materials continue to focus on AMT-130, an investigational gene therapy for Huntington's disease.
uniQure plans to announce its third-quarter 2026 financial results before the market opens on Wednesday, November 4. The company disclosed the date on its investor relations page.
Results date sets next catalyst
The release will be followed by an earnings update webcast scheduled for 8:30 a.m. to 9:30 a.m. Eastern Time on November 4. For investors, the publication and webcast provide the next scheduled opportunity to assess revenue, cash use and progress across uniQure's clinical programs.
uniQure's recent investor materials have highlighted AMT-130, an investigational gene therapy for Huntington's disease. The company also lists additional programs including AMT-260 for refractory mesial temporal lobe epilepsy and AMT-191 for Fabry disease.
uniQure stock traded at 24.30 euros on Lang & Schwarz at 13:04 Berlin time on Saturday, October 31, 2026. Investors can follow the real-time quote of uniQure stock.
uniQure stock facts
- Company: uniQure N.V.
- ISIN: NL0010696654
- Ticker: QURE
- Exchange: Lang & Schwarz
- Quote: 24.30 euros on Saturday, October 31, 2026, at 13:04 Berlin time
US biotechnology shares remain sensitive to clinical updates, regulatory milestones and financing expectations. See the latest S&P 500 market reports.
